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Background & aims: : The aim of this study was to investigate the spectrum of colonic microﬂora in
patients with colitis and if this could be altered with one month’s treatment with synbiotics.
Methods: This was a pilot study in which patients were randomised to either receive a synbiotics
preparation for a month and then “crossed over” to receive a placebo, or alternatively to receive the
placebo ﬁrst followed in the second month by synbiotic. Stool samples were collected on entry into the
study and then at the end of ﬁrst and second months respectively. Colonic microﬂora was measured by
terminal restriction fragment length polymorphism technique. Quantitative PCR was used to determine
the concentration of individual species.
Results: Sixteen patients completed the study of whom 8 had Crohn’s colitis and 8 had ulcerative colitis.
Their median age was 62 (IQR 50e65) years. An average of 22 terminal restriction fragments (T-RF’s) was
identiﬁed in each patient. Dice cluster analysis showed that each patient had a unique microbial
composition which did not change signiﬁcantly at different time points in the study, irrespective of
whether they had probiotics or the placebo. Probiotic organisms were identiﬁed in stool samples but did
not alter overall spectrum of microﬂora. In this pilot study we were unable to identify any speciﬁc
characteristics related to nature of colitis.
Conclusions: This study suggests that there is no difference in colonic microﬂora between patients with
Crohn’s or Ulcerative colitis and that the spectrum of bacteria was not altered by synbiotic
administration.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Inﬂammatory bowel disease (IBD) is characterised by recurring
inﬂammatory lesions of epithelial lining and lamina propria of the
bowel wall.1 The aetiology of IBD remains unknown but there is
increasing evidence to suggest that intestinal microﬂora may have
an important role. It is well recognised, for example, that diversion
of the faecal stream frequently results in disease remission which
relapse on restoration of intestinal continuity. Further, the identi-
ﬁcation of intracellular bacterial sensor genes suggests an impor-
tant role for bacteria in the natural history of IBD.1e5eeting of the Association of
ol, United Kingdom.
x: þ44 01723 354031.
ciates Ltd. Published by Elsevier LtA putative role for bacteria in the aetiology of IBD has been the
basis of many studies which have investigated the use of probiotics
in these patients. For example, studies have been reported in pa-
tients with acute colitis or in the remission, but results are incon-
sistent.8e10 A recent study has shown a beneﬁt for probiotics used
in combination with other therapy. Hegazy et al. demonstrated a
signiﬁcant decrease in the colonic mucosal concentration of IL-6,
expression of TNF-alpha and NF-kappa B p65, leukocyte recruit-
ment, and the level of faecal calprotectin in patients with ulcerative
colitis treated with probiotics and sulfasalazine compared to the
group on sulfasalazine alone.11 In animal models, probiotic prepa-
ration VSL#3 has been shown to alter composition of bacterial
microﬂora in colitis.12 Whether or not this might be the case in
humans, remains uncertain.
The aim of this small randomised double blind placebo controlled
crossover studywas to determine the spectrumof faecalmicroﬂora in
patients with colitis and attempt to determine if this could be altered
with oral synbiotics (a combination of pre and probiotics) therapy.d. All rights reserved.
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Fig. 1. Study design.
Fig. 2. T-RFLP gel and a complete comparison dendrogram based on a dice analysis. Each pa
pairwise similarity among the different patients had an average of 55%.
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A total of 20 patients were enrolled in this pilot study which was
designed as a randomized, double blind, placebo controlled trial.
Sixteen patients completed the study of which 8 had Crohn’s colitis
and 8 had ulcerative colitis. Two patients could not proceed due to
intolerance to synbiotic preparation. One patient became pregnant
after enrolment into the study andwas subsequently excluded from
analysis and one patient did not take the probiotic preparation as
recommended. All patients included in the study had histological
diagnosis of Crohn’s or ulcerative colitis and were recruited from
the combined IBD outpatient clinic at Scarborough hospital. Pa-
tients under 18 years of age were not included in this study and all
patients were in remission phase on recruitment and remained so
during the two months of study. Their disease activity was scored
by using Harvey Bradshaw Index (HBI) at the start of study, after
one month and at the completion of the study (Figs. 1 and 2). This
study was approved by the local ethic committee (LREC Number:tient had an average of 72% pairwise similarity independent of treatment, whereas the
Graph 1. Harvey Bradshaw index.
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department of Clinical Governance (SNAE 0803).
Synbiotic treatment: Trevis capsules, (Chr Hansen A/S,
Denmark) this is a commercially available multi-strain probiotic
preparation. It was administered orally in a dose of one capsule
three times a day for one month. It contains 4 strains of probiotics,
Lactobaccillus acidophilus LA-5, Lactobacillus delbrueckii subsp.
bulgaricus LBY-27, Biﬁdobacterium animalis subsp. lactis BB-12 and
Streptococcus thermophilus STY-31 in concentration of 4  109
organisms per capsule. Patients also received 15 g of oligofructose
powder, a prebiotic, each day. The combination of pre and probiotic
is termed synbiotic.
A biologically inactive preparation of probiotics was used as the
placebo in this study. These capsules were also prepared by
Christian Hansen and appeared identical to the active Trevis
capsules. Dextrose powder was used in place of the oligofructose in
the placebo group.
Randomisation: Patients were randomised using a series of
sealed envelopes into 2 groups by the pharmacy department of the
hospital, patients in group A were given placebo preparation for
one month and patients in group B were given the probiotic
preparation. After completion of one month both group were
crossed over so that patients in group A had probiotics during the
second month and patients in group B had placebo. The treating
clinicians, the research staff and the patients recruited to the study
were all blinded to the study medication. The randomisation code
was kept by the pharmacy department.
Three set of stool samples were collected: on entry into the
study and at the end of ﬁrst and second month’s treatment
respectively (samples a, b and c) Fig. 1. All patients continued their
regular medications throughout the study.Graph 2. Harvey Bradshaw index.2.1. Analysis of bacterial community in the stool samples
2.1.1. Terminal restriction fragment length polymorphism
The structure of the bacterial community was analysed using a
terminal restriction fragment length polymorphism (T-RFLP)
technique.13 Terminal restriction fragment (T-RF) patterns were
generated and analysed in a series of four consecutive steps: DNA
extraction, polymerase chain reaction (PCR), restriction enzyme
digestion and gel electrophoresis.
DNA extraction: Total DNAwas extracted from the faecal samples
by the stool DNA extraction kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s instructions except for an added
bead beating step. 200 mg of intestinal content were suspended in
1.4 ml of Buffer ASL (Qiagen) and homogenised with 400 mg of
100 mm Zirconiaesilica beads (BioSpec Products Inc., Bartlesville,
USA) using a minibead beater at high speed for 3 min (Biospec
Products Inc.). Subsequently, the suspension was centrifuged
(20 000  g, 1 min), the supernatant was transferred to a new
Eppendorf tube, and the stool kit procedure continued after the
lysis step in the protocol where the InhibitEX tablet is added. The
DNA was stored at 20 C until further analysis.
Terminal restriction fragment length polymorphism analyses: ter-
minal restriction fragment length polymorphism (T-RFLP) proﬁles
and analyses were performed as described by Mølbak.14 In short,
extracted total DNA was adjusted by spectrophotometry to a con-
centration of 5 mg of DNA/ml. Two replicate 50-ml PCRmixtures were
made from each sample using the universal bacterial primers S-D-
Bact-0008-a-S-20 (50-AGAGTTTGATCMTGGCTCAG-3015; and S-D-
Bact-0926lam-a-A-20 (50 CCGTCAATTCCTTTRAGTTT30)(14). Primer S-
D-Bact-0926lam-a-A-20 was 50FAM (carboxy-ﬂuorescein-N
hydroxysuccinimide-ester-dimethyl-sulfoxide) labelled. Puriﬁed PCR
products (200 ng) were digested with 20 U of HhaI Boehringer,
Mannheim, Germany) restriction enzyme in 20-ml reaction mixtures
for 3 h at 37 C. The two PCR replicateswere pooled into two samples,
which were analysed by electrophoresis on an automatic sequence
analyser (ABIPRISM-373-DNA-Sequencer; PE Biosystems, Foster City,
CA, USA). ABI traces were imported into BioNumerics version 4.5
(AppliedMaths, Sint-Martens-Latem, Belgium) and aligned using the
internal standardMegaBACEET900-Rsizestandard (GEHealthcare/
UK). Terminal restriction fragments (T-RFs)were foundbyautosearch
at a position tolerance of 0.2, and only T-RFs between 35 and 625 bp
observed in both PCR duplicates were included in the ﬁnal analysis.
The mean relative intensity of each T-RF within a sample was calcu-
lated by dividing the area of that individual peakwith the total area of
all peaks on the electropherogram. Since each T-RF ideally represents
a single species or taxonomic group of bacteria, it is possible to relate
the empirically found T-RFs to theoretically digested 16S rRNA genes
of bacteria. The Dice cluster analysis was performed to verify the
spectrumofbacteria and change in thepatternof the totalmicrobiota.
The dendrogram was a complete linkage based on the individually
dice cluster values and created by Bionumerics. The T-RFLP proﬁles
were further analysed by generating principal component analysis
(PCA) in Bionumerics both based on the quantitative band patterns
and binary values, Division by the variances over the entries and
subtraction of the averages over the characters were included in the
PCA.
As Bacteroides fragilis has been implicated in the aetiology of IBD
relative concentrations of B. fragilis DNA were determined at the
entry of the trial and after synbiotic and placebo treatment. This,
however, was not a primary end point of this study.
3. Results
In total, 48 samples were obtained from the 16 patients who
completed the study. Median age was 62 (IQR 50e65) years. Male
Fig. 3. Relative abundance values for terminal restriction fragments (T-RFs) obtained by using general bacterial primers and HhaI restriction digestion.
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measured at the start of study, after one month and at the end of
the study period. There were no signiﬁcant differences in HBI for
the study groups (Graph 1 and 2).
An average of 22 T-RFs was obtained from each fecal sample.
Dice cluster analysis showed that each patient had a unique mi-
crobial spectrumwhich was not changed at different time points in
the study following administration of either placebo or synbiotic.
The dendrogram conﬁrms the individual nature of the spectrum ofmicroﬂora demonstrating relatively little overlap between patients
(Fig. 2). With respect to the analysis of T-RFLP proﬁles, principal
component analysis (PCA) is a strong tool for comparison of com-
plex microbial communities. In this study no clustering related to
the probiotic treatment was seen (data not shown).
Compliance to study administration of probiotics was assessed
by the analysis of 16S rDNA sequences from the four probiotic
species found in Trevis. We identiﬁed 3 distinct restriction frag-
ments, which almost certainly relate to probiotic organisms
Fig. 4. B. fragilis DNA concentrations in samples from patients with Crohn’s (CD), or ulcerative colitis (UC). Concentration at entry level (A), concentration at two other sampling
points (B, or C). Sampling after probiotic treatment is indicated by black bars.
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B. animalis subsp. lactis ¼ 367 bp, S. thermophilus ¼ 582 bp, and L.
acidophilus ¼ 596 bp)). A fragment with the size corresponding to
L. delbrueckii was not found in the faecal T-RFLP proﬁles of any of
the 16 patients (Fig. 3). The relative abundance of the potential T-
RFs for the probiotic strains could not be related to the treatment as
they only accounted for a small part of the total bacterial
community.
The T-RFLP analysis of the stool samples from the 16 patients
showed differences in the quantity of a 102 bp T-RF related to the
probiotic treatment, but this difference was not statistically signiﬁ-
cant. As the 102 bp fragmentmight represent B. fragilis, quantitative
real-time PCR (Q-PCR) was used to determine the concentration of
B. fragilis DNA from the samples as previously published.16
The results of the Q-PCR determination of B. fragilis DNA are
shown in Fig. 4. Patients either had low levels of B. fragilis DNA (4
patients) or high levels (11 patients) on recruitment to the study.
The abundance of B. fragilis had no associationwith the disease type
(Crohn’s or UC) or disease activity (HBI index). Probiotic treatment
had no effect on the abundance of B. fragilis (Fig. 5).
4. Discussion
This small randomised double blinded placebo controlled trial
was designed as a pilot project to evaluate the feasibility of a larger
randomised controlled study to evaluate the effects of probiotics onFig. 5. Abundance of B. fragilis. Correlation between abundance of B. fragilis- DNA
determined by T-RFLP and Q-PCR.the colonic microﬂora of patients with colitis. This study suggests
that patients with colitis have a uniquemicrobial spectrum and this
does not change with the administration of synbiotics.
An interesting observation in this study was the bimodal prev-
alence of B. fragilis in patients with colitis. This commensal organ-
ism has been implicated in the initiation and exacerbation of colitis
in animal models.17 Its role in colitis and Crohn’s disease in humans
is less well understood.18 B. fragilis is a normal commensal in the
colonic microﬂora of adults. A subset of B. fragiliswhich secretes 20
a KDa pro-inﬂammatory toxin has recently been linked to IBD.
These bacteria have been identiﬁed in mucosal washings of pa-
tients with colitis and are associated with clinically active disease.18
Initial analysis of results in this study suggested a difference (non-
signiﬁcant) in T-RF 102 bp which could represent B. fragilis. As there
is growing evidence of association between Enterotoxigenic
B. fragilis (ETBF) and IBD (17,18), it was decided to performQ-PCR to
determine concentrations of this organism from the DNA obtained
from the stool samples although this was not in the initial study
design. As seen in Figs. 4 and 5, patients with colitis either had a low
or high concentration of B. fragilis on recruitment to the study in-
dependent of the type of colitis. Treatment with probiotics did not
have an effect on the abundance of B. fragilis. It must be emphasized
that in our study B. fragilis abundance was estimated in faecal
samples, and this may not reﬂect the concentration of mucosa-
associated B. fragilis. Mucosal-association may be a prerequisite
for manifestation of clinical symptoms. However, these ﬁndings
should be read with caution as the 16S rDNA targeted Q-PCR does
not distinguish ETBF from other strains belonging to Bacterioides
species.
There are a number of limitations in this study. The study could
be criticized because of small numbers but it is worthy of emphasis
that this was designed as a pilot study. No similar study exists in the
literature and power calculations to estimate numbers needed to
answer a hypothesis were therefore not possible. Further, as we
have found in earlier studies investigating effects of probiotics
recruitment to these studies is difﬁcult and persuading patients to
remain involved for the entirety of the study period is difﬁcult. In
this regard it is pertinent to record that we deliberately chose to
recruit patients in remission on the basis that they were likely to be
able to take oral preparations uninterrupted for 2 months and
because a primary end point of this study was an attempt to see if
J. Ahmed et al. / International Journal of Surgery 11 (2013) 1131e11361136
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crossover nature design of this study permitted an appropriate
control group.
Secondly, the probiotic treatment was used only for a period of 1
month and there was no washout period between using placebo
and probiotics in the study design. Whether or not using probiotics
for longer durations of time and introducing a washout period
between treatments would have had an impact on colonic micro-
ﬂora remains unanswered by this study design. We consider this
improbable. If administration of probiotics (with or without) pre-
biotics for one month has no impact on faecal ﬂora then it
improbable that longer periods of administration would do so.
Thirdly, it was not possible to relate the T-RFs that represent the
probiotic strains with treatment and only three of the four probiotic
organisms used in the Trevis capsule were identiﬁed in the T-FRLP
analysis. Although this does not mean its absence as the detection
limit of this technique is only 4000 values (2.5 decades of the most
abundant bacteria), its survival remains questionable. Whether or
not, using a higher concentration of the probiotic organisms might
have changed the results remains uncertain.
As previously highlighted in various articles,19e21 the effect of
probiotic treatment in human studies is often variable and there is
inconsistency between different clinical trials. This is undoubtedly
related to the fact that differentmulti-strain probiotic combinations
have been used in variable doses frequencies. It is therefore
impossible to draw clinically relevant conclusions on the effects of
probiotics in human studies as there is little scope formeta-analysis.
In conclusion, we can ﬁnd no evidence to support the hypoth-
esis that the spectrum of colonic microﬂora may have aetiological
signiﬁcance in patients with IBD. Further, this study suggests that
the oral administration of synbiotics has no impact on the spectrum
of colonic microﬂora.
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